Brokerages Set Teleflex Incorporated (NYSE:TFX) PT at $252.50

Teleflex Incorporated (NYSE:TFX) has received an average recommendation of “Moderate Buy” from the seven research firms that are covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $252.50.

Several equities analysts recently weighed in on TFX shares. Needham & Company LLC restated a “hold” rating on shares of Teleflex in a research report on Monday, December 16th. StockNews.com upgraded Teleflex from a “hold” rating to a “buy” rating in a research note on Thursday, November 28th. Mizuho decreased their price objective on Teleflex from $275.00 to $250.00 and set a “neutral” rating for the company in a report on Friday, November 1st. Truist Financial dropped their price objective on shares of Teleflex from $227.00 to $200.00 and set a “hold” rating on the stock in a report on Wednesday, December 18th. Finally, Royal Bank of Canada reduced their target price on shares of Teleflex from $275.00 to $245.00 and set an “outperform” rating for the company in a research note on Friday, November 1st.

Hedge Funds Weigh In On Teleflex

Institutional investors have recently added to or reduced their stakes in the business. Toronto Dominion Bank lifted its position in Teleflex by 5.9% during the fourth quarter. Toronto Dominion Bank now owns 24,961 shares of the medical technology company’s stock valued at $4,443,000 after purchasing an additional 1,395 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Teleflex during the 4th quarter worth $234,000. CSS LLC IL grew its position in Teleflex by 10.9% in the fourth quarter. CSS LLC IL now owns 2,550 shares of the medical technology company’s stock worth $454,000 after acquiring an additional 250 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Teleflex by 12.0% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 373,388 shares of the medical technology company’s stock valued at $66,456,000 after purchasing an additional 40,128 shares in the last quarter. Finally, Voloridge Investment Management LLC bought a new stake in Teleflex during the fourth quarter worth about $5,707,000. 95.62% of the stock is currently owned by institutional investors.

Teleflex Stock Up 3.2 %

Shares of NYSE:TFX opened at $174.74 on Thursday. Teleflex has a 1 year low of $165.62 and a 1 year high of $253.06. The company has a market capitalization of $8.12 billion, a PE ratio of 34.74, a price-to-earnings-growth ratio of 1.67 and a beta of 1.16. The business has a fifty day moving average price of $177.41 and a two-hundred day moving average price of $208.26. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.42 and a quick ratio of 1.39.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.